GLP-1 Strategy - Prime Therapeutics
Develop a holistic GLP-1 strategy
An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value and member health outcomes.
85%
Eighty-five percent of people who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for weight loss were no longer taking the drug after two years.
The evolution of GLP-1s
When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend.² So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program.
Holistic solutions for weight management
More than 73.1% of adults in the United States are either overweight or obese. In addition to the health impact, obesity costs the health care system almost $173B per year. Prime’s clinical insights report outlines where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and supporting a whole-person approach to sustainable weight management.
Next-level cardiometabolic support
Conditions like obesity, diabetes, hypertension and high cholesterol can compound if left unchecked, causing serious and costly health problems. KeepWell™ offers a personalized and effective path to wellness for your members, driving better outcomes across the cardiometabolic spectrum
Login Portals
Compliance / Legal
Careers
© 2024 Prime Therapeutics LLC